FINWIRES · TerminalLIVE
FINWIRES

Canaccord Genuity Initiates BridgeBio Pharma at Buy With $104 Price Target

By

BridgeBio Pharma (BBIO) has an average rating of buy and mean price target of $104.64, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

HC Wainwright Initiates Upstream Bio at Buy With $36 Price Target

Upstream Bio (UPB) has an average rating of buy and mean price target of $45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$UPB
Research

RBC Upgrades SSR Mining to Outperform From Sector Perform, Lowers Price Target to $40 From $45

SSR Mining (SSRM) has an average rating of buy and mean price target of $43.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SSRM
Research

RBC Downgrades Rio Tinto to Underperform From Sector Perform, Lifts Price Target to GBP64 From GBP63

Rio Tinto's (RIO) London stock has an average rating of overweight and mean price target of GBP74.49, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$RIO